In: PATENT NEWS
… use of the early disposition program in this investigation because it would impose unwarranted costs given that any decision “is likely to come after March 5, 2018,” which, the respondents contend, is the patent-in-suit’s expiration date. The presiding Administrative Law Judge subsequently scheduled a …
In: PATENT NEWS
BIOLASE Rejects Frivolous, Abusive Patent Litigation PR Newswire (press release) Full coverage
In: PATENT NEWS
If there’s one patent that I hope an automaker shelves for the remainder of human existence, it’s Ford’s patent for an autonomous police car. Ford recently received a patent for an autonomous system with a police car that can either act on its own or alongside a traditional human officer.... Continue reading
In: PATENT NEWS
Illumina wins $26.7 million in patent fight with Roche unit Ariosa Reuters Full coverage
In: PATENT NEWS
Searchmetrics Sees Victory Over BrightEdge Patent Infringement Suit MediaPost Communications Full coverage
In: PATENT NEWS
How exactly are patent rights lost through disclosure? Fundraising platforms enable startups and inventors to acquire financing and exposure but, at the same time, may require inventors or startups to disclose their inventions to the public. Under federal law, an inventor must file a patent application …
In: PATENT NEWS
The jury verdict, which came after two weeks of trial in Illston’s courtroom, is a milestone in the legal fight between the business-partners-turned-rivals. The parties and their affiliates have fought at the Federal Circuit five times and at the Patent Trial and Appeal Board at least five more times over... Continue reading
In: PATENT NEWS
After two days of deliberation, the eight-person jury found Ariosa’s Harmony prenatal test that checks a mother’s blood for early signs of fetal abnormalities infringed U.S. Patent Nos. 7,955,794 and 8,318,430, which protect methods for testing and analyzing DNA for chromosomes associated with genetic …
In: PATENT NEWS
The PTAB did not institute review on the ground that CRFD’s patent was obvious on Bates alone, finding that institution on that ground would be redundant. Ultimately, the PTAB concluded that the challenged claims were not anticipated or obvious on any of the instituted grounds, finding that Bates does …
In: PATENT NEWS
Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031 Markets Insider Full coverage
Designed by Industrial Action
Copyright © 2025 OPUS IP Limited. All Rights Reserved
OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION